The Spanish Medicines Agency has given Investigational Medicinal Products (IMP) License to Midatech Biogune to manufacture clinical grade nanoparticles at its Bilbao manufacturing facility, Spain.
Prior to licensing the manufacturing facility, the Spanish Medicines Agency has conducted inspection on 15 and 16 February 2011.Midatech claims its biocompatible nanoparticles possess a number of properties that make them ideal for diagnostic and therapeutic applications.
Their small size potentially enables drug delivery via different routes of administration, including parental, transdermal, mucosal, intradermal, transbuccal, sublingual or intranasal/inhalation.Midatech Biogune CEO Justin Barry said getting such a positive response from the Medicines Agency validates the quality of their manufacturing and endorses the investment that Midatech has made into its first class quality systems.
